Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer Group
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Nintedanib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms NEMO
- 25 Apr 2018 Planned End Date changed from 1 Jun 2020 to 1 Oct 2020.
- 25 Apr 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2019.
- 25 Apr 2018 Status changed from not yet recruiting to recruiting.